NASDAQ:CEMI - Chembio Diagnostics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 194.12 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
▼ -1.25 (-29.00%)

This chart shows the closing price for CEMI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Chembio Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CEMI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CEMI

Analyst Price Target is $9.00
▲ +194.12% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Chembio Diagnostics in the last 3 months. The average price target is $9.00, with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 194.12% upside from the last price of $3.06.

This chart shows the closing price for CEMI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Chembio Diagnostics. This rating has held steady since May 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/21/2021Colliers SecuritiesDowngradeBuy ➝ NeutralHigh
3/11/2021Colliers SecuritiesReiterated RatingBuy$8.00Medium
12/3/2020Craig HallumUpgradeHold ➝ Buy$5.00 ➝ $10.00Low
11/6/2020Colliers SecuritiesUpgradeNeutral ➝ Buy$7.50Low
6/17/2020Robert W. BairdDowngradeHold$4.00High
6/17/2020Colliers SecuritiesDowngradeBuy ➝ NeutralHigh
6/17/2020Craig HallumDowngradeBuy ➝ Hold$8.00High
6/17/2020BenchmarkDowngradeSpeculative Buy ➝ HoldHigh
6/17/2020Canaccord GenuityDowngradeBuy ➝ Hold$7.00High
5/26/2020Robert W. BairdInitiated CoverageOutperform$21.00High
4/23/2020Craig HallumBoost Price TargetBuy$15.00 ➝ $21.00Medium
4/15/2020Canaccord GenuityBoost Price TargetBuy$10.00 ➝ $12.00High
4/2/2020Canaccord GenuityReiterated RatingBuy$10.00Low
4/1/2020BenchmarkBoost Price TargetSpeculative Buy$4.00 ➝ $7.00High
3/26/2020Canaccord GenuityReiterated RatingBuy$7.00High
3/12/2020Canaccord GenuityReiterated RatingBuy$7.00High
3/4/2020BenchmarkLower Price TargetSpeculative Buy$9.00 ➝ $5.00High
7/22/2019Canaccord GenuityReiterated RatingBuy$10.00Low
6/17/2019BenchmarkLower Price TargetBuy$14.00 ➝ $9.00High
5/2/2019Canaccord GenuityReiterated RatingBuy$10.00Low
3/11/2019Canaccord GenuityReiterated RatingBuy$9.00Medium
2/7/2019Canaccord GenuityReiterated RatingBuy$9.00Medium
1/4/2019Canaccord GenuityInitiated CoverageBuy$9.00Low
12/19/2018Dougherty & CoInitiated CoverageBuy ➝ BuyMedium
7/11/2018BenchmarkInitiated CoverageBuy$14.00Low
11/11/2016BenchmarkSet Price TargetBuy$9.00N/A
8/14/2016BenchmarkReiterated RatingBuy$10.00 ➝ $9.00N/A
8/11/2016BenchmarkBoost Price TargetSpeculative Buy$9.00 ➝ $10.00N/A
(Data available from 7/25/2016 forward)
Chembio Diagnostics logo
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Read More

Today's Range

Now: $3.06
Low: $2.95
High: $4.06

50 Day Range

MA: $3.05
Low: $2.06
High: $5.34

52 Week Range

Now: $3.06
Low: $2.06
High: $8.75


24,041,379 shs

Average Volume

27,841,434 shs

Market Capitalization

$61.97 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Chembio Diagnostics?

The following equities research analysts have issued research reports on Chembio Diagnostics in the last twelve months: Colliers Securities, Craig Hallum, and Zacks Investment Research.
View the latest analyst ratings for CEMI.

What is the current price target for Chembio Diagnostics?

2 Wall Street analysts have set twelve-month price targets for Chembio Diagnostics in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 194.1%. Craig Hallum has the highest price target set, predicting CEMI will reach $10.00 in the next twelve months. Colliers Securities has the lowest price target set, forecasting a price of $8.00 for Chembio Diagnostics in the next year.
View the latest price targets for CEMI.

What is the current consensus analyst rating for Chembio Diagnostics?

Chembio Diagnostics currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CEMI will outperform the market and that investors should add to their positions of Chembio Diagnostics.
View the latest ratings for CEMI.

What other companies compete with Chembio Diagnostics?

How do I contact Chembio Diagnostics' investor relations team?

Chembio Diagnostics' physical mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The company's listed phone number is 631-924-1135 and its investor relations email address is [email protected] The official website for Chembio Diagnostics is